Plain-English translation of NCT06552559 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing whether a medication called , combined with a standard chemotherapy regimen, can help people with B-cell lymphoma that has spread to the brain or returned after previous treatment. The medication works by blocking a protein that cancer cells use to survive. Researchers hope that adding this treatment to chemotherapy will help more patients achieve remission and improve long-term outcomes.
When lymphoma spreads to the brain or comes back after treatment, it becomes very difficult to treat. Current standard therapies help fewer than half of patients, and many who do respond eventually experience relapse. This medication targets a different pathway in cancer cells, and researchers believe combining it with chemotherapy might provide better results than either treatment alone.
You likely qualify if…
You likely don't qualify if…
You would receive treatment in 3-week cycles. During each cycle, you would take the new medication () by mouth on specific days, and receive intravenous chemotherapy drugs (ifosfamide, carboplatin, and etoposide) and a steroid (dexamethasone) on other days. The first part of the trial focuses on finding the right dose of the new medication; the second part tests that dose combined with the chemotherapy. You would need regular blood tests and scans to monitor how you're responding, and you must be able to keep up with scheduled clinic visits throughout the study.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
South Korea